The authors suggested that SOX9 may be considered a biomarker for NAFLD because it is involved in liver metabolic diseases since NAFLD pathology involves both molecular pathways and cellular alterations33. Here, SOX9 is linked to metabolic dysfunction-associated steatotic liver disease.